BTAI - BioXcel Therapeutics, Inc.
| Previous Close | 11.02 |
| Open | 10.95 |
| Bid | 7.26 x 1400 |
| Ask | 0.00 x 900 |
| Day's Range | 10.64 - 10.95 |
| 52 Week Range | 2.41 - 14.79 |
| Volume | 25,140 |
| Avg. Volume | 34,879 |
| Market Cap | 171.384M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.42 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.50 |
- GlobeNewswire•7 days ago
BioXcel Therapeutics to Participate in the BMO 2019 Prescriptions for Success Healthcare Conference
NEW HAVEN, Conn., June 18, 2019 -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will.
- GlobeNewswire•15 days ago
BioXcel Therapeutics Completes Dosing Two Cohorts of Agitated Schizophrenia Patients with BXCL501 in a Phase 2 Efficacy Trial
BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (BTAI), announced today that it has completed dosing of the first two cohorts of agitated schizophrenia patients in its Phase 2 efficacy trial of BXCL501, the Company’s proprietary sublingual thin-film formulation of dexmedetomidine (“Dex”). BTI plans to use the results from this study to pursue two planned Phase 3 pivotal trials in agitated schizophrenia and bipolar disorder patients currently expected to begin in 4Q 2019. BTI is a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology.
- GlobeNewswire•19 days ago
BioXcel Therapeutics CEO, Dr. Vimal Mehta to Participate in BIO International Convention Panel on Innovative Clinical Trial Designs
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (BTAI), announced today that Dr. Vimal Mehta, Chief Executive Officer and Founder of BTI, will participate in a panel at the BIO International Convention in Philadelphia, PA. BTI is a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology.
- GlobeNewswire•22 days ago
BioXcel Therapeutics Announces FDA Clearance of IND Application for Triple Combination in Pancreatic Cancer and CTA Acceptance for Double Combination in Aggressive Form of Prostate Cancer (tNEPC) for Lead Immuno-Oncology Program, BXCL701
BioXcel Therapeutics, Inc. (BTI) (BTAI), today announced an update of its immuno-oncology program for BXCL701, an orally-available systemic innate-immune activator with dual mechanisms of action. BTI is a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology.
- GlobeNewswire•25 days ago
BioXcel Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference
NEW HAVEN, Conn., May 31, 2019 -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company utilizing novel artificial.
- GlobeNewswire•last month
BioXcel Therapeutics Achieved Targeted Exposures of BXCL501 Designed For Non-Invasive Acute Treatment of Agitation in Neuropsychiatric Diseases
BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (BTAI), today announced positive top line data from its Phase 1 pharmacokinetic (PK) (bioavailability) and safety study of BXCL501, a proprietary sublingual thin-film formulation of dexmedetomidine (Dex), for the acute treatment of agitation across multiple neuropsychiatric indications. Administration of BXCL501 in the Phase 1 pharmacokinetic and safety study successfully achieved targeted exposure levels that were observed to be therapeutic in the Company’s prior IV Dex study and BTI intends to advance BXCL501 into a Phase 2 trial to evaluate efficacy in agitated schizophrenia patients.
- GlobeNewswire•last month
BioXcel Therapeutics to Highlight Advances in the BXCL501 Program at 2019 Investor Event in New York City
BioXcel Therapeutics, Inc. (“BTI”) (BTAI), a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology, today announced that the Company will host an Investor Event on Wednesday, May 22, 2019 beginning at 8:30 a.m. ET in New York City. Key opinion leaders and BTI management team will highlight the advances in the clinical development of BXCL501 and its potential as a treatment option for acute agitation and other indications. BXCL501, a sublingual thin film of dexmedetomidine (Dex), is the most advanced drug asset in the Company’s pipeline.
- GlobeNewswire•2 months ago
BioXcel Therapeutics to Present at the 2019 UBS Global Healthcare Conference
NEW HAVEN, Conn., May 09, 2019 -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced, that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will.
- GlobeNewswire•2 months ago
BioXcel Therapeutics Reports First Quarter 2019 Results and Provides Business Update
On track to announce results in May 2019 from recently completed BXCL501 Phase 1 pharmacokinetic (bioavailability) and safety study Advanced manufacturing of BXCL501 thin film.
- GlobeNewswire•2 months ago
BioXcel Therapeutics Advances Process Development for BXCL501 Thin Film Formulation
Automated, scalable process developed for manufacturing clinical and commercial supply BXCL501 thin film architecture is proprietary and flexible for combination therapies.
- GlobeNewswire•2 months ago
BioXcel Therapeutics to Host First Quarter 2019 Financial Results and Business Update
NEW HAVEN, Conn., April 29, 2019 -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial.
- Simply Wall St.•2 months ago
Does BioXcel Therapeutics's (NASDAQ:BTAI) Share Price Gain of 46% Match Its Business Performance?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you want to compound wealth in the stock market, you can do so by buying an index fund. But y...
- GlobeNewswire•3 months ago
BioXcel Therapeutics to Present at Upcoming Investor Conferences in April
NEW HAVEN, Conn., April 03, 2019 -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced, that the Company will deliver corporate overview presentations at both.
- GlobeNewswire•3 months ago
BioXcel Therapeutics Showcases Data on BXCL701 in Combination with OX40 Agonist in Late-breaking Poster Presentation at AACR Annual Meeting
Novel combination achieves synergistic anti-tumor effect and survival benefit Demonstrates BXCL701’s potential ability to bridge innate and adaptive immune systems Clinical.
- GlobeNewswire•3 months ago
BioXcel Therapeutics Files Clinical Trial Application for the Development of BXCL701 and Pembrolizumab in Neuroendocrine Prostate Cancer (tNEPC)
BioXcel Therapeutics, Inc. (“BTI”) (BTAI) today announced that it has filed a Clinical Trial Application (CTA) with the U.K. health authorities for its lead immuno-oncology asset, BXCL701, an orally-available small molecule immune-modulator with dual mechanisms of action, in combination with pembrolizumab (Keytruda®), a checkpoint inhibitor, in tNEPC. BTI is a clinical-stage biopharmaceutical development company utilizing novel artificial intelligence approaches to identify the next wave of medicines across neuroscience and immuno-oncology.
- GlobeNewswire•3 months ago
BioXcel Therapeutics to Present at 29th Annual Oppenheimer Healthcare Conference
NEW HAVEN, Conn., March 13, 2019 -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced, that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will.
- GlobeNewswire•3 months ago
BioXcel Therapeutics Announces Late Breaking Data Presentation at AACR 2019 Annual Meeting
BioXcel Therapeutics, Inc. (“BTI”) (BTAI) today announced that it will present a late breaking poster featuring data from a preclinical study of the Company’s BXCL701 and an OX40-agonist antibody as a potential combination therapy for treatment of certain solid tumors at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2019 being held from March 29 to April 3, 2019 in Atlanta, Georgia. Dr. Vince O’Neill, Chief Medical Officer of BTI commented, “The encouraging results from this preclinical study of BXCL701 and an OX40 agonist, an investigational monoclonal antibody immunotherapy, represent a potentially valuable therapeutic option for cancer patients.
- GlobeNewswire•4 months ago
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2018 Quarterly Results and Provides Business Update
BXCL501 Pharmacokinetic (Bioavailability) and safety study on track to read out in second quarter 2019; initiation of Phase 2/3 Registration Trial expected in second half 2019.
- GlobeNewswire•4 months ago
BioXcel Therapeutics to Participate in Upcoming Investor Conferences in March
NEW HAVEN, Conn., March 05, 2019 -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced, that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will.
- GlobeNewswire•4 months ago
BioXcel Therapeutics Announces Addition of Merck KGaA, Darmstadt, Germany, and Pfizer to Clinical Collaboration with Nektar for Development of Triple-combination Therapy in Pancreatic Cancer
Clinical partnership to evaluate triple combination of BioXcel Therapeutics’ BXCL701, Nektar’s NKTR-214 and avelumab (Merck KGaA, Darmstadt, Germany and Pfizer) in pancreatic.
- GlobeNewswire•4 months ago
BioXcel Therapeutics to Host Fourth Quarter & Full Year 2018 Financial Results and Business Update Conference Call
NEW HAVEN, Conn., March 01, 2019 -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial.
- GlobeNewswire•5 months ago
BioXcel Therapeutics to Present at 2019 BIO CEO & Investor Conference
NEW HAVEN, Conn., Feb. 06, 2019 -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Chief Executive Officer of BTI, will.
- GlobeNewswire•5 months ago
BioXcel Therapeutics Expands Indication for Lead Neuroscience Asset, BXCL501, to Treat Symptoms Associated with Opioid Drug Withdrawal
BioXcel Therapeutics, Inc. (“BTI” or “Company”) (BTAI), today announced proof-of-concept data from its Phase 1b study of intravenously-administered dexmedetomidine (IV Dex) in patients suffering from opioid withdrawal symptoms. The positive data from this Phase 1b trial provides evidence to expand the potential market for BXCL501, a first in class proprietary sublingual film of Dex, beyond its current focus for acute treatment of agitation in neuropsychiatric indications.
- ACCESSWIRE•5 months ago
The Most Innovative Healthcare AI Developments of 2019
HOUSTON, TX / ACCESSWIRE / January 9, 2019 / Technology has changed in the blink of an eye. Concepts that were nothing more than science fiction, such as artificial intelligence (AI) and machine learning are now quickly disrupting global industries with significant capabilities. In fact, the limitless potential of AI alone is disrupting businesses, the way we conduct our affairs, and even the way financial institutions conduct high-frequency trading.
- Yahoo Finance Video•28 days ago
BioXcel Therapeutics, Inc. uses AI technology to develop drugs
Connecticut-based company, BioXcel Therapeutics, Inc., is using artificial intelligence technology to develop new drugs. The drug BXCL501 is on fast track to the FDA and is intended to treat bipolar, schizophrenia, dementia and opioid withdrawals. While BXCL701 is still in development with the hope to treat Pancreatic Cancer and an aggressive form of prostate cancer. Yahoo Finance breaks down that and more with the founder and CEO of BioXcel Therapeutics Dr. Vimal Mehta.
